The pain medication VX-548, developed by Vertex Pharmaceuticals, showed modest pain relief and was generally safe in late-stage trials. However, a debate started regarding the drug’s potential wide use if approved. The drug outperformed placebo in pain relief trials for abdominoplasty and bunion surgeries, with fewer adverse events than the placebo. However, it did not outperform a combination of acetaminophen and the opioid hydrocodone, leading to prescribing complications. The study did not specifically compare VX-548 and the opioid comparator, but results from three Phase 3 studies were overall positive. These results have sparked discussions about the drug’s potential market performance.
Source link
Vertex non-opioid pain medication trial results get a mixed reaction
